Chronic inducible urticaria (CIndU) encompasses various chronic urticaria subtypes caused by specific triggers. CIndU seems to be more resistant than chronic spontaneous urticaria (CSU) to standard doses of antihistamines, although claims data analysis reveals positive uptake trends among the more-recent second-generation antihistamines Clarinex and Claritin. Vistaril and montelukast are also key drugs in the CIndU therapy market and are often used in combination therapy. Indeed, current treatment guidelines recommend the use of leukotriene receptor antagonists (e.g., montelukast) as add-on treatment. Although no biologics have been approved for CIndU, we observe off-label use of certain biologics (e.g., TNF inhibitors, Roche / Novartis’s Xolair, Sanofi / Regeneron’s Dupixent) for this indication, mainly as later-line therapy. Thus, there is a market for more-effective drugs targeting CIndU.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
Geography: United States
Key drugs covered: Allegra, Zyrtec, Benadryl, montelukast, nifedipine, Vistaril, Silenor, Xolair, Dupixent, Humira, Remicade, Enbrel, Cimzia, Simponi
Key analysis provided: Brand / therapy usage across longitudinal patient sample; newly diagnosed patient analysis; treatment initiation and progression; line of therapy analysis; combination therapy analysis; source of business for recently treated patients; persistency and compliance analysis; product-level patient flowcharts